{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:46:03Z","timestamp":1777445163715,"version":"3.51.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,9]],"date-time":"2015-12-09T00:00:00Z","timestamp":1449619200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Angiogenesis"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s10456-015-9490-5","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T05:46:31Z","timestamp":1449726391000},"page":"79-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class"],"prefix":"10.1007","volume":"19","author":[{"given":"Hendrik","family":"Gille","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"H\u00fclsmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Trentmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Matschiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans J\u00fcrgen","family":"Christian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Amirkhosravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent P.","family":"Audoly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas M.","family":"Hohlbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Skerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,9]]},"reference":[{"key":"9490_CR1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3229","volume":"9","author":"AL Nelson","year":"2010","unstructured":"Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767\u2013774","journal-title":"Nat Rev Drug Discov"},{"key":"9490_CR2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4161\/mabs.27333","volume":"6","author":"JM Reichert","year":"2014","unstructured":"Reichert JM (2014) Antibodies to watch in 2014. mAbs 6:5\u201314","journal-title":"mAbs"},{"key":"9490_CR3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.copbio.2007.04.010","volume":"18","author":"A Skerra","year":"2007","unstructured":"Skerra A (2007) Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 18:295\u2013304","journal-title":"Curr Opin Biotechnol"},{"key":"9490_CR4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.febslet.2013.11.006","volume":"588","author":"A Richter","year":"2014","unstructured":"Richter A, Eggenstein E, Skerra A (2014) Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins. FEBS Lett 588:213\u2013218","journal-title":"FEBS Lett"},{"key":"9490_CR5","doi-asserted-by":"crossref","DOI":"10.1201\/9781498712736","volume-title":"Lipocalins","author":"B \u00c5kerstr\u00f6m","year":"2006","unstructured":"\u00c5kerstr\u00f6m B, Borregaard N, Flower DR, Salier J-S (2006) Lipocalins. Landes Bioscience, Georgetown"},{"key":"9490_CR6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0167-4838(00)00145-X","volume":"1482","author":"A Skerra","year":"2000","unstructured":"Skerra A (2000) Lipocalins as a scaffold. Biochim Biophys Acta 1482:337\u2013350","journal-title":"Biochim Biophys Acta"},{"key":"9490_CR7","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1021\/ar5003973","volume":"48","author":"A Schiefner","year":"2015","unstructured":"Schiefner A, Skerra A (2015) The menagerie of human lipocalins: a natural protein scaffold for molecular recognition of physiological compounds. Acc Chem Res 48:976\u2013985","journal-title":"Acc Chem Res"},{"key":"9490_CR8","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/j.1460-2075.1984.tb01995.x","volume":"3","author":"ME Newcomer","year":"1984","unstructured":"Newcomer ME, Jones TA, Aqvist J, Sundelin J, Eriksson U, Rask L, Peterson PA (1984) The three-dimensional structure of retinol-binding protein. EMBO J 3:1451\u20131454","journal-title":"EMBO J"},{"key":"9490_CR9","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1097-2765(02)00708-6","volume":"10","author":"DH Goetz","year":"2002","unstructured":"Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK (2002) The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 10:1033\u20131043","journal-title":"Mol Cell"},{"key":"9490_CR10","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1128\/AAC.48.9.3367-3372.2004","volume":"48","author":"M Fluckinger","year":"2004","unstructured":"Fluckinger M, Haas H, Merschak P, Glasgow BJ, Redl B (2004) Human tear lipocalin exhibits antimicrobial activity by scavenging microbial siderophores. Antimicrob Agents Chemother 48:3367\u20133372","journal-title":"Antimicrob Agents Chemother"},{"key":"9490_CR11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03104","volume":"432","author":"TH Flo","year":"2004","unstructured":"Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A (2004) Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432:917\u2013921","journal-title":"Nature"},{"key":"9490_CR12","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1073\/pnas.96.5.1898","volume":"96","author":"G Beste","year":"1999","unstructured":"Beste G, Schmidt FS, Stibora T, Skerra A (1999) Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc Natl Acad Sci USA 96:1898\u20131903","journal-title":"Proc Natl Acad Sci USA"},{"key":"9490_CR13","doi-asserted-by":"crossref","first-page":"8198","DOI":"10.1073\/pnas.0813399106","volume":"106","author":"D Sch\u00f6nfeld","year":"2009","unstructured":"Sch\u00f6nfeld D, Matschiner G, Chatwell L, Trentmann S, Gille H, H\u00fclsmeyer M, Brown N, Kaye PM, Schlehuber S, Hohlbaum AM, Skerra A (2009) An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc Natl Acad Sci USA 106:8198\u20138203","journal-title":"Proc Natl Acad Sci USA"},{"key":"9490_CR14","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jmb.2012.12.004","volume":"425","author":"M Gebauer","year":"2013","unstructured":"Gebauer M, Schiefner A, Matschiner G, Skerra A (2013) Combinatorial design of an Anticalin directed against the extra-domain B for the specific targeting of oncofetal fibronectin. J Mol Biol 425:780\u2013802","journal-title":"J Mol Biol"},{"key":"9490_CR15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0167-4838(00)00142-4","volume":"1482","author":"B Redl","year":"2000","unstructured":"Redl B (2000) Human tear lipocalin. Biochim Biophys Acta 1482:241\u2013248","journal-title":"Biochim Biophys Acta"},{"key":"9490_CR16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1074\/jbc.M410466200","volume":"280","author":"DA Breustedt","year":"2005","unstructured":"Breustedt DA, Kornd\u00f6rfer IP, Redl B, Skerra A (2005) The 1.8-\u00c5 crystal structure of human tear lipocalin reveals an extended branched cavity with capacity for multiple ligands. J Biol Chem 280:484\u2013493","journal-title":"J Biol Chem"},{"key":"9490_CR17","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1107\/S0907444909031011","volume":"65","author":"DA Breustedt","year":"2009","unstructured":"Breustedt DA, Chatwell L, Skerra A (2009) A new crystal form of human tear lipocalin reveals high flexibility in the loop region and induced fit in the ligand cavity. Acta Crystallogr D Biol Crystallogr 65:1118\u20131125","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"9490_CR18","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1158\/1535-7163.MCT-13-0318","volume":"12","author":"SA Olwill","year":"2013","unstructured":"Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, H\u00fclsmeyer M, Trentmann S, Jensen K, Hohlbaum AM, Audoly L (2013) A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity. Mol Cancer Ther 12:2459\u20132471","journal-title":"Mol Cancer Ther"},{"key":"9490_CR19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669\u2013676","journal-title":"Nat Med"},{"key":"9490_CR20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/362841a0","volume":"362","author":"KJ Kim","year":"1993","unstructured":"Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841\u2013844","journal-title":"Nature"},{"key":"9490_CR21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/labinvest.3700526","volume":"87","author":"F Shojaei","year":"2007","unstructured":"Shojaei F, Ferrara N (2007) Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab Invest 87:227\u2013230","journal-title":"Lab Invest"},{"key":"9490_CR22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391\u2013400","journal-title":"Nat Rev Drug Discov"},{"key":"9490_CR23","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","volume":"300","author":"SR Nalluri","year":"2008","unstructured":"Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277\u20132285","journal-title":"JAMA"},{"key":"9490_CR24","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","volume":"99","author":"FA Scappaticci","year":"2007","unstructured":"Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232\u20131239","journal-title":"J Natl Cancer Inst"},{"key":"9490_CR25","doi-asserted-by":"crossref","first-page":"18363","DOI":"10.1073\/pnas.0708865104","volume":"104","author":"JS Rudge","year":"2007","unstructured":"Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, Papadopoulos N, Pyles EA, Torri A, Wiegand SJ, Thurston G, Stahl N, Yancopoulos GD (2007) VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA 104:18363\u201318370","journal-title":"Proc Natl Acad Sci USA"},{"key":"9490_CR26","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1073\/pnas.0611492104","volume":"104","author":"HP Gerber","year":"2007","unstructured":"Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, Fuh G, Olsson C, Damico L, Xie D, Meng YG, Gutierrez J, Corpuz R, Li B, Hall L, Rangell L, Ferrando R, Lowman H, Peale F, Ferrara N (2007) Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci USA 104:3478\u20133483","journal-title":"Proc Natl Acad Sci USA"},{"key":"9490_CR27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1538-7836.2008.03212.x","volume":"7","author":"T Meyer","year":"2009","unstructured":"Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, Amaya M, Francis JL, Amirkhosravi A (2009) Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 7:171\u2013181","journal-title":"J Thromb Haemost"},{"key":"9490_CR28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/(SICI)1097-0134(199611)26:3<353::AID-PROT9>3.0.CO;2-E","volume":"26","author":"HW Christinger","year":"1996","unstructured":"Christinger HW, Muller YA, Berleau LT, Keyt BA, Cunningham BC, Ferrara N, de Vos AM (1996) Crystallization of the receptor binding domain of vascular endothelial growth factor. Proteins 26:353\u2013357","journal-title":"Proteins"},{"key":"9490_CR29","first-page":"257","volume":"74","author":"A Skerra","year":"2001","unstructured":"Skerra A (2001) \u2018Anticalins\u2019: a new class of engineered ligand-binding proteins with antibody-like properties. J Biotechnol 74:257\u2013275","journal-title":"J Biotechnol"},{"key":"9490_CR30","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1074\/jbc.M002016200","volume":"276","author":"H Gille","year":"2001","unstructured":"Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N (2001) Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 276:3222\u20133230","journal-title":"J Biol Chem"},{"key":"9490_CR31","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/S0002-9440(10)65044-4","volume":"156","author":"K Miyamoto","year":"2000","unstructured":"Miyamoto K, Khosrof S, Bursell SE, Moromizato Y, Aiello LP, Ogura Y, Adamis AP (2000) Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 156:1733\u20131739","journal-title":"Am J Pathol"},{"key":"9490_CR32","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/S0161-6420(96)30420-X","volume":"103","author":"MJ Tolentino","year":"1996","unstructured":"Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, Ferrara N, Adamis AP (1996) Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 103:1820\u20131828","journal-title":"Ophthalmology"},{"key":"9490_CR33","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nrd2157","volume":"5","author":"R Narayanan","year":"2006","unstructured":"Narayanan R, Kuppermann BD, Jones C, Kirkpatrick P (2006) Ranibizumab. Nat Rev Drug Discov 5:815\u2013816","journal-title":"Nat Rev Drug Discov"},{"key":"9490_CR34","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179\u20132182","journal-title":"Ophthalmology"},{"key":"9490_CR35","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0169-409X(02)00022-4","volume":"54","author":"MJ Roberts","year":"2002","unstructured":"Roberts MJ, Bentley MD, Harris JM (2002) Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54:459\u2013476","journal-title":"Adv Drug Deliv Rev"},{"key":"9490_CR36","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1124\/mol.105.014910","volume":"68","author":"S Kubetzko","year":"2005","unstructured":"Kubetzko S, Sarkar CA, Pl\u00fcckthun A (2005) Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol 68:1439\u20131454","journal-title":"Mol Pharmacol"},{"key":"9490_CR37","first-page":"1029","volume":"146","author":"HF Dvorak","year":"1995","unstructured":"Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029\u20131039","journal-title":"Am J Pathol"},{"key":"9490_CR38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/019262339902700104","volume":"27","author":"J Mordenti","year":"1999","unstructured":"Mordenti J, Thomsen K, Licko V, Chen H, Meng YG, Ferrara N (1999) Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol 27:14\u201321","journal-title":"Toxicol Pathol"},{"key":"9490_CR39","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0969-2126(98)00116-6","volume":"6","author":"YA Muller","year":"1998","unstructured":"Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, de Vos AM (1998) VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4\u00a0\u00c5 resolution and mutational analysis of the interface. Structure\u00a06:1153\u20131167","journal-title":"Structure"},{"key":"9490_CR40","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.4049\/jimmunol.162.7.4311","volume":"162","author":"SE McKenzie","year":"1999","unstructured":"McKenzie SE, Taylor SM, Malladi P, Yuhan H, Cassel DL, Chien P, Schwartz E, Schreiber AD, Surrey S, Reilly MP (1999) The role of the human Fc receptor Fc\u03b3RIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol 162:4311\u20134318","journal-title":"J Immunol"},{"key":"9490_CR41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10456-012-9302-0","volume":"16","author":"A Stahl","year":"2013","unstructured":"Stahl A, Stumpp MT, Schlegel A, Ekawardhani S, Lehrling C, Martin G, Gulotti-Georgieva M, Villemagne D, Forrer P, Agostini HT, Binz HK (2013) Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications. Angiogenesis 16:101\u2013111","journal-title":"Angiogenesis"},{"key":"9490_CR42","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/019262339902700507","volume":"27","author":"J Mordenti","year":"1999","unstructured":"Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, Fourre KM, Ryan AM (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27:536\u2013544","journal-title":"Toxicol Pathol"},{"key":"9490_CR43","doi-asserted-by":"crossref","first-page":"e83232","DOI":"10.1371\/journal.pone.0083232","volume":"8","author":"K Mross","year":"2013","unstructured":"Mross K, Richly H, Fischer R, Scharr D, Buchert M, Stern A, Gille H, Audoly LP, Scheulen ME (2013) First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors. PLoS One 8:e83232","journal-title":"PLoS One"},{"key":"9490_CR44","unstructured":"EPAR (2006) Avastin: EPAR\u2014Scientific Discussion. European Medicines Agency; http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000582\/WC500029262.pdf"},{"key":"9490_CR45","first-page":"6253","volume":"60","author":"HP Gerber","year":"2000","unstructured":"Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N (2000) Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60:6253\u20136258","journal-title":"Cancer Res"},{"key":"9490_CR46","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1074\/jbc.M508199200","volume":"281","author":"WC Liang","year":"2006","unstructured":"Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik AK, Gerber HP, Ferrara N, Fuh G (2006) Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281:951\u2013961","journal-title":"J Biol Chem"},{"key":"9490_CR47","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1167\/iovs.07-1175","volume":"49","author":"L Yu","year":"2008","unstructured":"Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C, Fuh G, Lowman H, Ferrara N (2008) Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 49:522\u2013527","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9490_CR48","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581\u2013611","journal-title":"Endocr Rev"},{"key":"9490_CR49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.mvr.2010.02.001","volume":"80","author":"A Akeson","year":"2010","unstructured":"Akeson A, Herman A, Wiginton D, Greenberg J (2010) Endothelial cell activation in a VEGF-A gradient: relevance to cell fate decisions. Microvasc Res 80:65\u201374","journal-title":"Microvasc Res"},{"key":"9490_CR50","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/1752-0509-5-193","volume":"5","author":"SD Finley","year":"2011","unstructured":"Finley SD, Engel-Stefanini MO, Imoukhuede PI, Popel AS (2011) Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. BMC Syst Biol 5:193","journal-title":"BMC Syst Biol"},{"key":"9490_CR51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/abio.2001.5380","volume":"299","author":"LC Santora","year":"2001","unstructured":"Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K (2001) Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 299:119\u2013129","journal-title":"Anal Biochem"},{"key":"9490_CR52","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00280-009-1118-2","volume":"65","author":"T Leal","year":"2010","unstructured":"Leal T, Robins HI (2010) Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: a case report. Cancer Chemother Pharmacol 65:399\u2013401","journal-title":"Cancer Chemother Pharmacol"},{"key":"9490_CR53","first-page":"695430","volume":"2012","author":"J Kumar","year":"2012","unstructured":"Kumar J, Bhargava M, Aggarwal S (2012) Bevacizumab-induced reversible thrombocytopenia in a patient with adenocarcinoma of colon: rare adverse effect of bevacizumab. Case Rep Oncol Med 2012:695430","journal-title":"Case Rep Oncol Med"},{"key":"9490_CR54","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1517\/14712598.7.3.405","volume":"7","author":"I Walle Van","year":"2007","unstructured":"Van Walle I, Gansemans Y, Parren PW, Stas P, Lasters I (2007) Immunogenicity screening in protein drug development. Expert Opin Biol Ther 7:405\u2013418","journal-title":"Expert Opin Biol Ther"},{"key":"9490_CR55","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbapap.2005.12.006","volume":"1764","author":"DA Breustedt","year":"2006","unstructured":"Breustedt DA, Sch\u00f6nfeld DL, Skerra A (2006) Comparative ligand-binding analysis of ten human lipocalins. Biochim Biophys Acta 1764:161\u2013173","journal-title":"Biochim Biophys Acta"},{"key":"9490_CR56","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1006\/jmbi.2000.3646","volume":"297","author":"S Schlehuber","year":"2000","unstructured":"Schlehuber S, Beste G, Skerra A (2000) A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. J Mol Biol 297:1105\u20131120","journal-title":"J Mol Biol"},{"key":"9490_CR57","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1021\/ja806857r","volume":"131","author":"HJ Kim","year":"2009","unstructured":"Kim HJ, Eichinger A, Skerra A (2009) High-affinity recognition of lanthanide(III) chelate complexes by a reprogrammed human lipocalin 2. J Am Chem Soc 131:3565\u20133576","journal-title":"J Am Chem Soc"},{"key":"9490_CR58","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0378-1119(94)90643-2","volume":"151","author":"A Skerra","year":"1994","unstructured":"Skerra A (1994) Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in Escherichia coli. Gene 151:131\u2013135","journal-title":"Gene"},{"key":"9490_CR59","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1113\/jphysiol.1952.sp004789","volume":"118","author":"AA Miles","year":"1952","unstructured":"Miles AA, Miles EM (1952) Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs. J Physiol 118:228\u2013257","journal-title":"J Physiol"},{"key":"9490_CR60","first-page":"143","volume":"54","author":"L Simpson-Herren","year":"1970","unstructured":"Simpson-Herren L, Lloyd HH (1970) Kinetic parameters and growth curves for experimental tumor systems. Cancer Chemother Rep 54:143\u2013174","journal-title":"Cancer Chemother Rep"}],"container-title":["Angiogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-015-9490-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10456-015-9490-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-015-9490-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T03:28:07Z","timestamp":1692156487000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10456-015-9490-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,9]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["9490"],"URL":"https:\/\/doi.org\/10.1007\/s10456-015-9490-5","relation":{},"ISSN":["0969-6970","1573-7209"],"issn-type":[{"value":"0969-6970","type":"print"},{"value":"1573-7209","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,9]]}}}